Tanvex BioPharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	442.24	878.71	376.96	380.75	786.23	2,223
Cash & Short-Term Investments	442.24	878.71	376.96	380.75	786.23	2,223
Cash Growth	-58.95%	133.11%	-1.00%	-51.57%	-64.63%	7.46%
Accounts Receivable	120.16	67.32	0.07	9.4	0.33	2.52
Other Receivables	88.25	89.3	31.58	27.43	27.36	25.31
Receivables	208.41	156.62	31.65	36.83	27.69	27.84
Inventory	410.24	420.71	217.84	108.29	170.84	90.33
Prepaid Expenses	42.04	40.09	49.18	78.35	58.95	60.85
Other Current Assets	0.67	1.06	-	-	-	-
Total Current Assets	1,104	1,497	675.62	604.21	1,044	2,402
Property, Plant & Equipment	2,827	2,761	1,827	1,928	2,151	2,114
Goodwill	2,956	2,910	-	-	-	-
Other Intangible Assets	474.2	485.32	7.07	3.38	12.07	10.17
Long-Term Deferred Tax Assets	6.34	6.34	-	-	-	-
Other Long-Term Assets	271.22	301.22	225.3	227.67	213.47	187.58
Total Assets	7,638	7,961	2,735	2,763	3,420	4,714
Accounts Payable	52.62	102.99	-	-	-	-
Accrued Expenses	181.3	147.64	134.27	-	115.93	137.49
Short-Term Debt	135	30	-	-	-	-
Current Portion of Leases	190.15	181.63	160.01	163.45	124.65	88.75
Current Income Taxes Payable	26.89	26.89	-	-	-	-
Current Unearned Revenue	119.5	79.3	11.11	6.91	28.07	-
Other Current Liabilities	122.01	231.21	42.75	193.38	34.63	22.28
Total Current Liabilities	827.46	799.66	348.14	363.73	303.29	248.51
Long-Term Leases	1,351	1,367	1,488	1,568	1,715	1,670
Long-Term Unearned Revenue	93.59	99	5.47	10.23	-	-
Other Long-Term Liabilities	1.72	1.72	-	-	10.47	-
Total Liabilities	2,274	2,267	1,842	1,942	2,028	1,919
Common Stock	2,650	2,649	1,641	1,340	3,527	3,525
Additional Paid-In Capital	18,908	18,906	13,567	12,431	11,061	10,988
Retained Earnings	-16,025	-15,637	-14,136	-12,755	-12,969	-11,327
Comprehensive Income & Other	-168.39	-223.63	-177.94	-194.17	-227.09	-390.12
Shareholders' Equity	5,364	5,694	893.31	821.11	1,391	2,795
Total Liabilities & Equity	7,638	7,961	2,735	2,763	3,420	4,714
Total Debt	1,676	1,578	1,648	1,732	1,839	1,759
Net Cash (Debt)	-1,234	-699.69	-1,271	-1,351	-1,053	463.95
Net Cash Growth	-	-	-	-	-	-15.52%
Net Cash Per Share	-4.83	-2.86	-8.19	-10.48	-8.95	4.27
Filing Date Shares Outstanding	264.99	264.86	164.07	133.96	117.64	117.57
Total Common Shares Outstanding	264.99	264.86	164.07	133.96	117.64	117.57
Working Capital	276.13	697.52	327.48	240.48	740.43	2,153
Book Value Per Share	20.24	21.50	5.44	6.13	11.83	23.77
Tangible Book Value	1,934	2,298	886.24	817.73	1,379	2,785
Tangible Book Value Per Share	7.30	8.68	5.40	6.10	11.73	23.68
Machinery	1,156	1,126	1,089	982.54	975.18	889.53
Construction In Progress	934.52	849.55	44.34	83.71	72.82	53.8
Leasehold Improvements	527.52	517.23	509.94	415.69	388.62	318.95